Work

Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial

Year: 2023

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet. Gastroenterology & hepatology

DOI: 10.1016/s2468-1253(23)00198-x

Authors: Mazen Noureddin, Shaharyar Khan, Francisco Portell, Diane Jorkasky, Jameel Dennis, Omer Khan, Lars Johansson, Edvin Johansson, Arun J Sanyal

Institutions: Houston Methodist, Houston Methodist Research Institute, Rivus Pharmaceuticals, Inc. (United States), Antaros Medical (Sweden), Virginia Commonwealth University, Virginia Commonwealth University Medical Center

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4387380939

FWCI: 8.547

Cites: 34

Cited by: 43

Related to: 10